Fasting protects against the side effects of irinotecan treatment but does not affect anti-tumour activity in mice

British Journal of Pharmacology

Volumn 173, Issue 5, 2016, Pages 804-814

  Huisman, Sander A ^a   De Bruijn, Peter ^b   Ghobadi Moghaddam Helmantel, Inge M ^b   Ijzermans, Jan N M ^a   Wiemer, Erik A C ^b   Mathijssen, Ron H J ^b   De Bruin, Ron W F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FIRTECAN; IRINOTECAN; 7-ETHYL-10-HYDROXYCAMPTOTHECIN GLUCURONIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOXYLESTERASE; CES2 PROTEIN, MOUSE; GLUCURONIDE; MESSENGER RNA;

ADVERSE DRUG REACTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BAGG ALBINO MOUSE; BODY WEIGHT; C26 CELL LINE; CANCER TISSUE; CARCINOMA CELL LINE; COLON CARCINOMA; CONTROLLED STUDY; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG TISSUE LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; COLONIC NEOPLASMS; DIARRHEA; DRUG EFFECTS; GENETICS; LEUKOPENIA; LIVER; METABOLISM; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR VOLUME; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARBOXYLIC ESTER HYDROLASES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DIARRHEA; FASTING; GLUCURONIDES; LEUKOPENIA; LIVER; MALE; MICE, INBRED BALB C; RNA, MESSENGER; TREATMENT OUTCOME; TUMOR BURDEN; WEIGHT LOSS;

EID: 84958794164     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13317     Document Type: Article

References (47)

1. Adam R, (2007). Colorectal cancer with synchronous liver metastases. Br J Surg 94: 129-131.
2. Aidoo A, Desai VG, Lyn-Cook LE, Chen JJ, Feuers RJ, Casciano DA, (1999). Attenuation of bleomycin-induced Hprt mutant frequency in female and male rats by calorie restriction. Mutat Res 430: 155-163.
3. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al,. (2015). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024-6109.
4. Apte UM, Limaye PB, Desaiah D, Bucci TJ, Warbritton A, Mehendale HM, (2003). Mechanisms of increased liver tissue repair and survival in diet-restricted rats treated with equitoxic doses of thioacetamide. Toxicol Sci: An Off J Society Toxicol 72: 272-282.
5. Cao S, Bhattacharya A, Durrani FA, Fakih M, (2006). Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Expert Opin Pharmacother 7: 687-703.
6. Chen Y, Jungsuwadee P, Vore M, Butterfield DA, St. Clair DK, (2007). Collateral damage in cancer chemotherapy: Oxidative stress in nontargeted tissues. Mol Interv 7: 147-156.
7. Conklin KA, (2004). Chemotherapy-associated oxidative stress: Impact on chemotherapeutic effectiveness. Integr Cancer Ther 3: 294-300.
8. de Bruijn P, Willems EW, Loos WJ, Verweij J, Sparreboom A, (2004). Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples. Anal Biochem 328: 84-86.
9. de Bruijn P, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A, (1997). Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 698: 277-285.
10. de Jong FA, de Jonge MJ, Verweij J, Mathijssen RH, (2006). Role of pharmacogenetics in irinotecan therapy. Cancer Lett 234: 90-106.
11. Di Paolo A, Bocci G, Danesi R, Del Tacca M, (2006). Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients. Curr Clin Pharmacol 1: 311-323.
12. Fitzpatrick LR, Small JS, Greene WH, Karpa KD, Keller D, (2011). Bacillus coagulans GBI-30 (BC30) improves indices of Clostridium difficile-induced colitis in mice. Gut Pathog 3: 16.
13. Harvie MN, Pegington M, Mattson MP, Frystyk J, Dillon B, Evans G, et al,. (2011). The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: A randomized trial in young overweight women. Int J Obes (Lond) 35: 714-727.
14. Huisman SA, Bijman-Lagcher W, IJzermans JNM, Smits R, de Bruin RW, (2015). Fasting protects against the side effects of irinotecan but preserves its anti-tumor effect in Apc15lox mutant mice. Cell Cycle 1-7.
15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, (2011). Global cancer statistics. CA Cancer J Clin 61: 69-90.
16. Johnson JB, Summer W, Cutler RG, Martin B, Hyun DH, Dixit VD, et al,. (2007). Alternate day calorie restriction improves clinical findings and reduces markers of oxidative stress and inflammation in overweight adults with moderate asthma. Free Radic Biol Med 42: 665-674.
17. Jongbloed F, de Bruin RW, Pennings JL, Payan-Gomez C, van den Engel S, van Oostrom CT, et al,. (2014). Preoperative fasting protects against renal ischemia-reperfusion injury in aged and overweight mice. PLoS One 9: E100853. doi: 10.1371/journal.pone.0100853. eCollection 2014.
18. Kim TW, Innocenti F, (2007). Insights, challenges, and future directions in irinogenetics. Ther Drug Monit 29: 265-270.
19. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: The ARRIVE guidelines. Br J Pharmacol 160: 1557-1579.
20. Kohle C, Bock KW, (2007). Coordinate regulation of phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2. Biochem Pharmacol 73: 1853-1862.
21. Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, et al,. (2012). Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med 4 124ra127.
22. Longo VD, Mattson MP, (2014). Fasting: Molecular mechanisms and clinical applications. Cell Metab 19: 181-192.
23. Mathijssen RH, Sparreboom A, Verweij J, (2014). Determining the optimal dose in the development of anticancer agents. Nat Rev Clin Oncol 11: 272-281.
24. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al,. (2001). Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res: An Off J Am Assoc for Cancer Res 7: 2182-2194.
25. Mattson MP, (2008a). Hormesis defined. Ageing Res Rev 7: 1-7.
26. Mattson MP, (2008b). Dietary factors, hormesis and health. Ageing Res Rev 7: 43-48.
27. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: The ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
28. Mitchell JR, Verweij M, Brand K, van de Ven M, Goemaere N, van den Engel S, et al,. (2010). Short-term dietary restriction and fasting precondition against ischemia reperfusion injury in mice. Aging Cell 9: 40-53.
29. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, Spedding M, Yu W, Harmar AJ,; NC-IUPHAR. (2014) The IUPHAR/BPS Guide to PHARMACOLOGY: An expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Res 42 (Database Issue): D1098-1106.
30. Peng W, Robertson L, Gallinetti J, Mejia P, Vose S, Charlip A, et al,. (2012). Surgical stress resistance induced by single amino acid deprivation requires Gcn2 in mice. Sci Transl Med 4: 118ra111.
31. Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G, et al,. (2008). Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A 105: 8215-8220.
32. Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson JR, Rahman A, et al,. (2007). The role of SN-38 exposure, UGT1A128 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol 47: 78-86.
33. Rothenberg ML, (1998). Efficacy and toxicity of irinotecan in patients with colorectal cancer. Semin Oncol 25: 39-46.
34. Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen TL, et al,. (1994). Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54: 427-436.
35. Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, et al,. (2009). Fasting and cancer treatment in humans: A case series report. Aging 1: 988-1007.
36. Sato N, Michaelides MC, Wallack MK, (1981). Characterization of tumorigenicity, mortality, metastasis, and splenomegaly of two cultured murine colon lines. Cancer Res 41: 2267-2272.
37. Scartozzi M, Mandolesi A, Giampieri R, Pierantoni C, Loupakis F, Zaniboni A, et al,. (2010). Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. Int j of Cancer J Int du Cancer 127: 1941-1947.
38. Sparreboom A, de Bruijn P, de Jonge MJ, Loos WJ, Stoter G, Verweij J, et al,. (1998). Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces. J Chromatogr B Biomed Sci Appl 712: 225-235.
39. Sun D, Muthukumar AR, Lawrence RA, Fernandes G, (2001). Effects of calorie restriction on polymicrobial peritonitis induced by cecum ligation and puncture in young C57BL/6 mice. Clin Diagn Lab Immunol 8: 1003-1011.
40. van Ginhoven TM, van den Berg JW, Dik WA, Ijzermans JN, de Bruin RW, (2010a). Preoperative dietary restriction reduces hepatic tumor load by reduced E-selectin-mediated adhesion in mice. J Surg Oncol 102: 348-353.
41. Van Ginhoven TM, Van Den Berg JW, Dik WA, Ijzermans JN, De Bruin RW, (2010b). Preoperative fasting induces protection against renal ischemia/reperfusion injury by a corticosterone-independent mechanism. Transplant int.: Off j of the European Soc for Organ. Transplantation 23: 1171-1178.
42. van Ginhoven TM, Mitchell JR, Verweij M, Hoeijmakers JH, Ijzermans JN, de Bruin RW, (2009). The use of preoperative nutritional interventions to protect against hepatic ischemia-reperfusion injury. Liver Transpl: Off Pub of the Am Assoc for the Stud of Liver Dis and the Int Liver Transpl Soc 15: 1183-1191.
43. van Ginhoven TM, de Bruin RW, Timmermans M, Mitchell JR, Hoeijmakers JH, Ijzermans JN, (2011). Pre-operative dietary restriction is feasible in live-kidney donors. Clin Transplant 25: 486-494.
44. Verweij M, van Ginhoven TM, Mitchell JR, Sluiter W, van den Engel S, Roest HP, et al,. (2011). Preoperative fasting protects mice against hepatic ischemia/reperfusion injury: Mechanisms and effects on liver regeneration. Liver Transplantation: Off Pub of the Am Assoc for the Study of Liver Dis and the Int Liver Transplantation Soc 17: 695-704.
45. Withers SS, Kass PH, Rodriguez CO, Jr., Skorupski KA, O'Brien D, Guerrero TA, et al,. (2014). Fasting reduces the incidence of delayed-type vomiting associated with doxorubicin treatment in dogs with lymphoma. Transl Oncol 2014 pii: S1936-5233(14)00049-7. doi: 10.1016/j.tranon.2014.04.014. [Epub ahead of print]
46. Xu G, Zhang W, Ma MK, McLeod HL, (2002). Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res: An Off J of the Am Assoc for Cancer Res 8: 2605-2611.
47. Yang CS, Brady JF, Hong JY, (1992). Dietary effects on cytochromes P450, xenobiotic metabolism, and toxicity. FASEB J: Off Pub of the Fed of Am Soc for Exp Bio 6: 737-744.